The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
A Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Varenicline Tartrate for Alcohol Dependence
Open accessAbstract
OBJECTIVES: To assess the efficacy and safety of varenicline (Chantix) for the treatment of alcohol dependence. Varenicline is a partial α4β2 nicotinic acetylcholine agonist approved by the Food and Drug Administration for smoking cessation. It has reduced drinking in animal studies and in small studies of humans who were both heavy drinkers and smokers. This is the first multisite clinical trial of varenicline in a population of smokers and nonsmokers with alcohol dependence. METHODS: Men and women (n = 200) meeting the criteria for alcohol dependence were recruited across 5 clinical sites. Patients received double-blind varenicline or placebo and a computerized behavioral intervention. Varenicline was titrated during the first week to 2 mg/d, which was maintained during weeks 2 to 13. RESULTS: The varenicline group had significantly lower weekly percent heavy drinking days (primary outcome) (adjusted mean difference = 10.4), drinks per day, drinks per drinking day, and alcohol craving compared with the placebo group (P < 0.05). The average treatment effect on alcohol use was similar for smokers and nonsmokers. Varenicline was well-tolerated; adverse events were expected and mild. CONCLUSIONS: Varenicline significantly reduced alcohol consumption and craving, making it a potentially viable option for the treatment of alcohol dependence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There was no evidence of association between nicotinic receptor genes or pathways with DrnkWk, despite the use of nicotinic receptor partial agonists (e.g., varenicline) in the treatment of alcohol dependence33.”
From Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use (2019) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M. A., Amann, M., Anderson, H. R., Andrews, K. G., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61766-8 · Cited by 11,805
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
(1998) · PubMed · Cited by 10,216
A simulation study of the number of events per variable in logistic regression analysis
Peduzzi, P., Concato, J., Kemper, E., Holford, T. R., & Feinstein, A. R. (1996) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(96)00236-3 · Cited by 9,655
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D. V., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,899
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870
Cited by
Sorted by citations
23andMe Research Team, Liu, M., Psychiatry, H. A.-I., Jiang, Y., Wedow, R., Li, Y., Brazel, D. M., Chen, F., Datta, G., Davila-Velderrain, J., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0307-5 · Cited by 1,896
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Advances in the science and treatment of alcohol use disorder
Witkiewitz, K. A., Litten, R. Z., & Leggio, L. (2019) · Science Advances · doi:10.1126/sciadv.aax4043 · Cited by 629
Self-citationSubstance Abuse Among Older Adults
Kuerbis, A., Sacco, P., Blazer, D. G., & Moore, A. A. (2014) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2014.04.008 · Cited by 505
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Connor, J. P., Haber, P. S., & Hall, W. D. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00122-1 · Cited by 389
Kazdin, A. E. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108993647.010 · Cited by 279
Alcohol Use in Patients with Chronic Liver Disease
Fuster, D., & Samet, J. H. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1715733 · Cited by 207
Treatment of alcohol use disorders in patients with alcoholic liver disease
Addolorato, G., Mirijello, A., Barrio, P., & Gual, A. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.029 · Cited by 198
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
Cognitive control in alcohol use disorder: deficits and clinical relevance
Wilcox, C. E., Dekonenko, C. J., Mayer, A. R., Bogenschutz, M. P., & Turner, J. A. (2013) · Reviews in the Neurosciences · doi:10.1515/revneuro-2013-0054 · Cited by 174
An overview of alcohol and tobacco/nicotine interactions in the human laboratory
Verplaetse, T. L., & McKee, S. A. (2016) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2016.1189927 · Cited by 162
Thomas, K. H., Martin, R. M., Knipe, D. W., Higgins, J. P. T., & Gunnell, D. (2015) · BMJ · doi:10.1136/bmj.h1109 · Cited by 155
Thomas, K. H., Dalili, M. N., López-López, J. A., Keeney, E., Phillippo, D., Munafo, M. R., Stevenson, M., Caldwell, D. M., & Welton, N. J. (2021) · Health Technology Assessment · doi:10.3310/hta25590 · Cited by 163
State-of-the-art behavioral and pharmacological treatments for alcohol use disorder
Ray, L. A., Bujarski, S., Grodin, E. N., Hartwell, E. E., Green, R., Venegas, A., Lim, A. C., Gillis, A. J., & Miotto, K. A. (2018) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1528265 · Cited by 136
Louvet, A., Labreuche, J., Moreno, C., Vanlemmens, C., Moirand, R., Féray, C., Dumortier, J., Pageaux, G.-P., Bureau, C., Chermak, F., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00430-1 · Cited by 136
Falk, D. E., O’Malley, S. S., Witkiewitz, K., Anton, R. F., Litten, R. Z., Slater, M., Kranzler, H. R., Mann, K. F., Hasin, D. S., Johnson, B., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3079 · Cited by 120
Self-citationCarbone, M., Nardi, A., Flack, S., Carpino, G., Varvaropoulou, N., Gavrila, C., Spicer, A., Badrock, J., Bernuzzi, F., Cardinale, V., et al. (2018) · HAL · doi:10.1016/s2468-1253 · Cited by 119
Pharmacotherapy for alcohol dependence: status of current treatments
Franck, J., & Jayaram-Lindström, N. (2013) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2013.05.005 · Cited by 107
Varenicline for Treatment of Alcohol Dependence: A Randomized, Placebo‐Controlled Trial
de Bejczy, A., Löf, E., Walther, L., Guterstam, J., Hammarberg, A., Asanovska, G., Franck, J., Isaksson, A., & Söderpalm, B. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12854 · Cited by 107
Nicotine receptor partial agonists for smoking cessation
Livingstone‐Banks, J., Fanshawe, T. R., Thomas, K. H., Theodoulou, A., Hajizadeh, A., Hartman, L., & Lindson, N. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub8 · Cited by 108
Medications for alcohol use disorders: An overview
Akbar, M. D., Egli, M., Cho, Y., Song, B., & Noronha, A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.007 · Cited by 101
Reduced Drinking in Alcohol Dependence Treatment, What Is the Evidence?
Mann, K., Aubin, H.-J., & Witkiewitz, K. (2017) · European Addiction Research · doi:10.1159/000481348 · Cited by 93
Suchankova, P., Steensland, P., Fredriksson, I., Engel, J. A., & Jerlhag, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071284 · Cited by 95
Developing neuroscience-based treatments for alcohol addiction: A matter of choice?
Heilig, M. A., Augier, E., Pfarr, S., & Sommer, W. H. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0591-6 · Cited by 104
Litten, R. Z., Wilford, B. B., Falk, D. E., Ryan, M. L., & Fertig, J. B. (2016) · Substance Abuse · doi:10.1080/08897077.2015.1133472 · Cited by 94
Self-citationPharmacotherapy for Alcohol Use Disorder
Swift, R. M., & Aston, E. R. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000079 · Cited by 97
O’Malley, S. S., Zweben, A., Fucito, L. M., Wu, R., Piepmeier, M. E., Ockert, D. M., Bold, K. W., Petrakis, I. L., Muvvala, S. B., Jatlow, P. I., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3544 · Cited by 94
Falk, D. E., Ryan, M. L., Fertig, J. B., Devine, E. G., Cruz, R., Brown, E. S., Burns, H., Salloum, I. M., Newport, D. J., Mendelson, J., et al. (2019) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13917 · Cited by 89
Self-citationSoyka, M., Kranzler, H. R., HESSELBROCK, V. M., Kasper, S. F., Mutschler, J., Möller, H., & The WFSBP Task Force on Treatment Guidelines for Substance Use Disorders (2016) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1246752 · Cited by 87
Pharmacotherapy of alcoholism – an update on approved and off-label medications
Soyka, M., & Müller, C. A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1349098 · Cited by 97
Pharmacological approaches to reducing craving in patients with alcohol use disorders
Haass-Koffler, C. L., Leggio, L., & Kenna, G. A. (2014) · CNS Drugs · doi:10.1007/s40263-014-0149-3 · Cited by 83
Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder
Archibald, L. J. (2019) · Alcohol research · doi:10.35946/arcr.v40.1.06 · Cited by 85
Research Design in Clinical Psychology
Kazdin, A. E. (2021) · doi:10.1017/9781108993647 · Cited by 240
Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors
Wang, J., & Lindstrom, J. M. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13745 · Cited by 82
Ponizovsky, A. M., Rosca, P., Aronovich, E., Weizman, A., & Grinshpoon, A. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.11.007 · Cited by 80
for the National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) Study Group, Ryan, M. L., Falk, D. E., Fertig, J. B., Rendenbach-Mueller, B., Katz, D. A., Tracy, K. A., Strain, E. C., Dunn, K. E., Kampman, K., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.214 · Cited by 72
Self-citationFeduccia, A. A., Simms, J. A., Mill, D., Yi, H. Y., & Bartlett, S. E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12690 · Cited by 70
Nicotine receptor partial agonists for smoking cessation
Livingstone‐Banks, J., Fanshawe, T. R., Thomas, K. H., Theodoulou, A., Hajizadeh, A., Hartman, L., & Lindson, N. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub9 · Cited by 77
Litten, R. Z., Falk, D. E., Ryan, M. L., & Fertig, J. B. (2016) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13093 · Cited by 73
Self-citationThe Glycine Receptor—A Functionally Important Primary Brain Target of Ethanol
Söderpalm, B., Lidö, H. H., & Ericson, M. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13483 · Cited by 68
Feltmann, K., Borroto‐Escuela, D. O., Rüegg, J., Pinton, L., de Oliveira Sergio, T., Narváez, M., Jimenez‐Beristain, A., Ekström, T. J., Fuxe, K., & Steensland, P. (2018) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13568 · Cited by 67
Current pharmacological treatment approaches for alcohol dependence
Müller, C. A., Geisel, O., Banas, R., & Heinz, A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.876008 · Cited by 64
Tonstad, S., Arons, C., Rollema, H., Berlin, I., Hájek, P., Fagerström, K. O., Els, C., McRae, T. D., & Russ, C. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1729708 · Cited by 66
Varenicline in the Treatment of Alcohol Use Disorders
Erwin, B. L., & Slaton, R. M. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014545806 · Cited by 62
Wilcox, C. E., Abbott, C., & Calhoun, V. D. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.06.011 · Cited by 67
Yardley, M. M., & Ray, L. A. (2016) · Addiction Biology · doi:10.1111/adb.12349 · Cited by 62
Witkiewitz, K., Falk, D. E., Kranzler, H. R., Litten, R. Z., Hallgren, K. A., O'Malley, S. S., Anton, R. F., & Workgroup, I. C. W. T. A. C. T. I. (. (2014) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12543 · Cited by 60
Self-citationAddiction, cognitive decline and therapy: Seeking ways to escape a vicious cycle
Perry, C. J., & Lawrence, A. J. (2017) · Genes, Brain and Behavior · doi:10.1111/gbb.12325 · Cited by 60
Schacht, J. P., Anton, R. F., Randall, P. K., Li, X., Henderson, S., & Myrick, H. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3518-1 · Cited by 59
Tsai, P.-C., Bake, S., Balaraman, S., Rawlings, J. A., Holgate, R., DuBois, D. W., & Miranda, R. C. (2014) · Biology Open · doi:10.1242/bio.20147765 · Cited by 59
Falk, D. E., Castle, I. P., Ryan, M., Fertig, J. B., & Litten, R. Z. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000133 · Cited by 61
Self-citationNicotinic receptor modulation to treat alcohol and drug dependence
Rahman, S., Engleman, E. A., & Bell, R. L. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00426 · Cited by 60
Management of alcohol use disorder in patients with chronic liver disease
Mellinger, J. L., Fernandez, A. C., & Winder, G. S. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000145 · Cited by 52
Substance use in older HIV-infected patients
Edelman, E. J., Tetrault, J. M., & Fiellin, D. A. (2014) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000069 · Cited by 49
Treatment-refractory substance use disorder: focus on alcohol, opioids, and cocaine
Soyka, M., & Mutschler, J. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.003 · Cited by 49
Alcohol use disorder in community management of chronic liver diseases
Leggio, L., & Mellinger, J. L. (2022) · Hepatology · doi:10.1002/hep.32531 · Cited by 51
Hurt, R. T., Ebbert, J. O., Croghan, I. T., Schroeder, D. R., Hurt, R. D., & Hays, J. T. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.11.017 · Cited by 48
Management of alcohol use disorder: a gastroenterology and hepatology-focused perspective
Díaz, L. A., König, D., Weber, S., Ayares, G., Fuentealba, J. M., Vázquez, V., Bataller, R. A., Kamath, P. S., Winder, G. S., Leggio, L., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00380-7 · Cited by 51
Emerging pharmacotherapies for alcohol use disorder
Mason, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.04.032 · Cited by 47
Practical outpatient pharmacotherapy for alcohol use disorder
Kim, Y., Hack, L. M., Ahn, E. S., & Kim, J. (2018) · Drugs in Context · doi:10.7573/dic.212308 · Cited by 47
Leggio, L., Zywiak, W. H., Edwards, S. M., Tidey, J. W., Swift, R. M., & Kenna, G. A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3652-9 · Cited by 46
The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?
Pomrenze, M. B., Fetterly, T. L., Winder, D. G., & Messing, R. O. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13507 · Cited by 46
Morley, K. C., Perry, C. J., Watt, J., Hurzeler, T. P., Leggio, L., Lawrence, A. J., & Haber, P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1892641 · Cited by 44
Medications for treating alcohol use disorder: A narrative review
Kranzler, H. R., & Hartwell, E. E. (2023) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15118 · Cited by 50
Overcoming the “Valley of Death” in Medications Development for Alcohol Use Disorder
Ray, L. A., Bujarski, S., Roche, D. J. O., & Magill, M. (2018) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13829 · Cited by 42
Perez, E. E., Cardé, N. A. Q., & Biasi, M. D. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.80 · Cited by 46
Rohsenow, D. J., Tidey, J. W., Martin, R. A., Colby, S. M., Swift, R. M., Leggio, L., & Monti, P. M. (2017) · Addiction · doi:10.1111/add.13861 · Cited by 40
Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse
Skike, C. E. V., Maggio, S. E., Reynolds, A. R., Casey, E. M., Bardo, M. T., Dwoskin, L. P., Prendergast, M., & Nixon, K. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.004 · Cited by 43
Miranda, R., O’Malley, S. S., Padovano, H. T., Wu, R., Falk, D. E., Ryan, M. L., Fertig, J. B., Chun, T. H., Muvvala, S. B., & Litten, R. Z. (2020) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14352 · Cited by 37
Self-citationRay, L. A., Green, R., Enders, C. K., Leventhal, A. M., Grodin, E. N., Li, G., Lim, A. C., Hartwell, E. E., Venegas, A., Meredith, L. R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20070993 · Cited by 36
Roche, D. J. O., Ray, L. A., Yardley, M. M., & King, A. C. (2016) · Current Addiction Reports · doi:10.1007/s40429-016-0081-3 · Cited by 39
Funk, D. R., Lo, S. S. W., Coen, K. M., & Lê, A. D. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.09.009 · Cited by 36
Fredriksson, I., Jayaram-Lindström, N., Wirf, M., Nylander, E., Nyström, E., Jardemark, K., & Steensland, P. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.294 · Cited by 35
Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review
Fischler, P. V., Soyka, M., Seifritz, E., & Mutschler, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927703 · Cited by 34
Pharmacotherapies and Personalized Medicine for Alcohol Use Disorder: A Review
Lohoff, F. W. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0079 · Cited by 37
Blanco-Gandía, M. C., & Rodríguez‐Arias, M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.08.007 · Cited by 35
Chichetto, N. E., Kundu, S., Freiberg, M. S., Butt, A. A., Crystal, S., So-Armah, K. A., Cook, R. L., Braithwaite, R. S., Fiellin, D. A., Khan, M. R., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz188 · Cited by 34
Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies
Leggio, L., Falk, D. E., Ryan, M. L., Fertig, J. B., & Litten, R. Z. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_295 · Cited by 32
Self-citationVarenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial
McRae‐Clark, A. L., Gray, K. M., Baker, N. L., Sherman, B. J., Squeglia, L. M., Sahlem, G. L., Wagner, A. M., & Tomko, R. L. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109111 · Cited by 30
Effects of Varenicline on Neural Correlates of Alcohol Salience in Heavy Drinkers
Vatsalya, V., Gowin, J. L., Schwandt, M. L., Momenan, R., Coe, M. A., Cooke, M. E., Hommer, D. W., Bartlett, S. E., Heilig, M. A., & Ramchandani, V. A. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv068 · Cited by 30
Litten, R. Z., Falk, D. E., Ryan, M. L., Fertig, J. B., & Leggio, L. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14233 · Cited by 31
Self-citationFeltmann, K., Fredriksson, I., Wirf, M., Schilström, B., & Steensland, P. (2015) · Addiction Biology · doi:10.1111/adb.12304 · Cited by 30
Witkiewitz, K. A., Anton, R. F., O’Malley, S. S., Hasin, D. S., Silverman, B. L., Aldridge, A., Mann, K. F., Kranzler, H. R., Aubin, H., Hoffman, M., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.2508 · Cited by 29
Cippitelli, A., Schoch, J., Debevec, G., Brunori, G., Zaveri, N. T., & Toll, L. (2016) · Scientific Reports · doi:10.1038/srep26594 · Cited by 29
Dopamine and Alcohol Dependence: From Bench to Clinic
Jayaram‐Lindström, N., Ericson, M., Steensland, P., & Jerlhag, E. (2016) · InTech eBooks · doi:10.5772/63144 · Cited by 30
Anton, R. F., Latham, P. K., Voronin, K. E., Randall, P. K., Book, S. W., Hoffman, M., & Schacht, J. P. (2018) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13601 · Cited by 29
Mobile alcohol biosensors and pharmacotherapy development research
Roberts, W., & McKee, S. A. (2018) · Alcohol · doi:10.1016/j.alcohol.2018.07.012 · Cited by 31
Advances in Pharmacotherapy Development: Human Clinical Studies
Litten, R. Z., Falk, D. E., Ryan, M. L., Fertig, J. B., & Leggio, L. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_79 · Cited by 29
Self-citationGhin, F., Beste, C., & Stock, A. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.12.031 · Cited by 32
Schoeler, T., Baldwin, J. R., Allegrini, A. G., Barkhuizen, W., McQuillin, A., Pirastu, N., Kutalik, Z., & Pingault, J. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.07.027 · Cited by 27
Alcohol use disorder in alcohol-associated liver disease: Two sides of the same coin
Singal, A. K., Leggio, L., & DiMartini, A. F. (2023) · Liver Transplantation · doi:10.1097/lvt.0000000000000296 · Cited by 28
Management of Alcohol Use Disorder in Patients Requiring Liver Transplant
Lee, M. R., & Leggio, L. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040567 · Cited by 26
Field, M., Lemma, L. C. G. D., Christiansen, P., & Dickson, J. M. (2016) · Psychology of Addictive Behaviors · doi:10.1037/adb0000232 · Cited by 27
The role of varenicline on alcohol-primed self-administration and seeking behavior in rats
Randall, P. A., Jaramillo, A. A., Frisbee, S., & Besheer, J. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3878-1 · Cited by 25
Lacroix, F., Pettorelli, A., Maddux, J.-M. N., Heidari-Jam, A., & Chaudhri, N. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.254 · Cited by 24
Gubner, N. R., McKinnon, C. S., & Phillips, T. J. (2014) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12588 · Cited by 23
Effects of varenicline on alcohol cue reactivity in heavy drinkers
Roberts, W., Harrison, E. L., & McKee, S. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4667-9 · Cited by 20
DeBaker, M. C., Moen, J. K., Robinson, J. M., Wickman, K. D., & Lee, A. M. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05426-6 · Cited by 24
Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders
Akerman, S. C., Brunette, M. F., Noordsy, D. L., & Green, A. I. (2014) · Current Addiction Reports · doi:10.1007/s40429-014-0034-7 · Cited by 23
Self-citation
Metadata
- Authors
- Litten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, D. A., Sarid-Segal, O., Kampman, K., Brunette, M. F., Strain, E. C., Tiouririne, N. A., Ransom, J., Scott, C., & Stout, R.
- Affiliations
- Boston University (US)
- National Institutes of Health (US)
- University of Virginia (US)
- Dartmouth College (US)
- University of Pennsylvania (US)
- Johns Hopkins University (US)
- Fast Track Drugs and Biologics (US)
- Pacific Institute For Research and Evaluation (US)
- Corresponding author
- Litten, Raye Z.
- ORCID
- Venue
- Journal of Addiction Medicine
- Published
- 2013-07
- Volume
- 7
- Issue
- 4
- Pages
- 277-286
- ISSN
- 1932-0620 (ISSN-L)
- PMC
- PMC3914416
- OpenAlex
- W2006833508
- Cited by
- 287
- References
- 47
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 10 · 2023: 25 · 2022: 9 · 2021: 40 · 2020: 21 · 2019: 24 · 2018: 25 · 2017: 26 · 2016: 26 · 2015: 25 · 2014: 26 · 2013: 7
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Addiction Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (4k24da023186-10)
- U.S. Public Health Service (HHSN27200900005C)
- National Institute on Alcohol Abuse and Alcoholism
- National Institute on Drug Abuse (K24-DA023186)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HHSN275200900005C)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- varenicline, alcoholism, nicotinic agonists, alcohol craving, heavy drinking, smoking cessation, drug efficacy, drug safety
- MeSH terms
- Varenicline, Adult, Alcoholism, Benzazepines, Double-Blind Method, Female, Humans, Male, Middle Aged, Quinoxalines, Treatment Outcome, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
